Fondaparinux-related thrombocytopenia in a patient with former HIT. Response to Rota et al. (Thromb Haemost 2008; 99: 779–781)

• References

• 1 Arepally GM, Ortel TL. Heparin-induced thrombocytopenia. New Engl J Med 2006; 355: 809-817.
• 2 Greinacher A, Eichler P, Lubenow N. et al. Drug-induced and drug-dependent immune thrombocytopenias. Rev Clin Exp Hematol 2001; 05: 166-200.
• 3 Lo GK, Juhl D, Warkentin TE. et al. Evaluation of pretest clinical score (4T`s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006; 04: 757-758.
• 4 Lo GK, Sigouin CS, Warkentin TE. What is the potential for overdiagnosis of heparininduced thrombocytopenia?. Am J Hematol 2007; 82: 1037-1043.
• 5 Warkentin TE, Cook RJ, Marder VJ. et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood 2005; 106: 3791-3796.
• 6 Pouplard C, Couvret C, Regina S. et al. Development of antibodies specific to polyanion-modified platelet factor 4 during treatment with fondaparinux. J Thromb Haemost 2005; 03: 2813-2815.
• 7 Lindhoff-Last E, Gerdsen F, Ackermann H. et al. Determination of heparin-platelet factor 4-IgG antibodies improves diagnosis of heparin-induced thrombocytopenia. Br J Haematol 2001; 113: 886-890.
• 8 Schwarzinger I, Speiser W, Lubenow N. et al. Heparin-platelet factor (PF) 4 antibodies in patients with pseudothrombocytopenia: coincidence or association?. Thromb Haemost 2000; 84: 1123-1124.
• 9 Alpert D, Mandl LA, Erkan D. et al. Anti-heparin platelet factor 4 antibodies in systemic lupus erythematosus are associated with IgM antiphospholipid antibodies and the antiphospholipid syndrome. Ann Rheum Dis 2008; 67: 395-401.
• 10 Magnani HN, Gallus A. Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004. Thromb Haemost 2006; 95: 967-981.
• 11 Schindewolf M, Mosch G, Bauersachs RM. et al. Safe anticoagulation with danaparoid in pregnancy and lactation. Thromb Haemost 2004; 92: 211.
• 12 Greinacher A, Alban S, Dummel V. et al. Characterization of the structural requirements for a carbohydrate based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia. Thromb Haemost 1995; 74: 886-892.
• 13 Schindewolf M, Luxembourg B, Lindhoff-Last E. Use of fondaparinux in patients with heparin-induced thrombocytopenia type II. Vasa 2006; 35: 70 Abstract.
• 14 Lobo B, Finch C, Howard A. et al. Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia. Thromb Haemost 2008; 99: 208-214.
• 15 Efird LE, Kockler DR. Fondaparinux for thromboembolic treatment and prophylaxis of heparin-induced thrombocytopenia. Ann Pharmacother 2006; 40: 1383-1387.